




## Non-small cell lung cancer (NSCLC)



**21.76%** have EGFR mutation-positive non-squamous disease

**By Disease Subtype**


**28.80%** have squamous disease




**12.02%** have ALK rearrangement-positive non-squamous disease

**37.42%** have non-squamous disease that is neither EGFR mutation-positive nor ALK rearrangement-positive, or have unknown mutational status

### Disease definitions and diagnosis of non-squamous and squamous histologies



### Stage IV patients by line of treatment



## Immunotherapies in the NSCLC treatment space

The success of PD-1/ PD-L1 targeted immunotherapies has led to a flurry of development, and their role in the treatment of NSCLC is expected to grow significantly in the coming years.

### Currently approved immunotherapies:

1. Keytruda (pembrolizumab; Merck & Co)  
– first- and second-line PD-L1-positive disease
2. Opdivo (nivolumab; Bristol-Myers Squibb/ Ono Pharmaceutical)  
– second-line disease
3. Tecentriq (atezolizumab; Roche/Chugai)  
– second-line disease

### Late-phase pipeline immunotherapies:

1. avelumab (Merck KGaA/Pfizer)
2. durvalumab (AstraZeneca)

